DIGITAL BIOLOGY
Features
BMS plans NVIDIA Vera Rubin deployment to expand drug discovery computing
The planned DGX SuperPOD will support foundation models trained on BMS's proprietary data and agentic workflows across its therapeutic programs. BMS says Vera Rubin delivers up to ten times greater performance per megawatt than its predecessor. The investment extends nearly three years of collaboration with NVIDIA; the reported performance and expected pipeline benefits are company claims.
Dassault Systèmes agrees to acquire ArisGlobal for approximately $1.8 billion
The deal includes up to $200 million in additional payments tied to AI-related revenue milestones. ArisGlobal's compliance platform serves over 200 customers and processes more than 12 million patient safety cases annually. The companies plan to combine those patient insights with Dassault's research, clinical development and manufacturing technology. Closing is expected in the second half of 2026.
A-Alpha Bio names GSK and model builders in its antibody data consortium
Founding members include GSK, Boltz, Cradle and Dyno Therapeutics. Members design experimental datasets each quarter, which A-Alpha Bio generates through AlphaSeq and pools for shared access. The company projects approximately 28 million affinity measurements per member annually at launch. The initial roadmap targets de novo antibody design and zero-shot optimization.
Asimov joins NSF-backed cloud laboratory to model therapeutic protein manufacturability
At Boston University's node, Asimov will build capacity to produce and characterize therapeutic proteins at high throughput. Computational designs will be made and tested in the lab, with results fed back into models intended to predict manufacturability from DNA sequences. The node will receive up to $20 million over four years as part of NSF's national cloud laboratory network.
Epitome Therapeutics launches with €4 million to develop precision epigenome editing
The EMBL spin-off aims to regulate gene expression without changing the underlying DNA sequence. Its CADENCE platform is designed for durable, tunable activation of genes, targeting conditions including rare genetic and metabolic disorders. The initial funding combines investment and grants. It will support platform development, scientific hiring and programs moving toward drug candidate selection.